-
Featured Authors
-
Archives
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: rare diseases
The Washington Post Unfairly Attacks The Orphan Drug Act
The Orphan Drug Act has been a tremendous success and addressed a market failure by providing incentives to bring new treatments to those suffering with rare diseases. That’s why I was deeply troubled by Friday’s unfair article in The Washington Post targeting the Orphan Drug Act through selective and unsubstantiated attacks that seem designed to undermine this bipartisan and hugely successful regime that has helped so many patients with rare diseases live longer and healthier Read More >
Complexities of Rare Diseases Take the Spotlight at BIO
Global Genes Founder & CEO Nicole Boice opened the BIO 2015 Orphan & Rare Disease Track by addressing a packed session with a simple, powerful statement: “We’re all working to eliminate the challenges of rare diseases, but patients and their advocates aren’t always equipped to fight.” Organizations like Global Genes help families affected by rare disease by connecting them with much needed tools and resources. By better understanding the definition of a “rare” disease, industry Read More >
New PhRMA Report: A Decade of Innovation in Rare Diseases
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released “A Decade of Innovation in Rare Diseases,” which highlights 10 years of progress in understanding rare diseases and drug development resulting in groundbreaking therapies. According to the report, more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development. The Read More >
Mito What???
Mitochondrial Disease: The Most Common Disease You’ve Probably Never Heard of… About 20 years ago, mitochondrial disease was virtually unheard of. Just 10 years ago, it was considered rare. Today, according to NORD, a disease is considered rare when less than 200,000 people are affected. Mitochondrial disease is not a single disease, but rather an entire umbrella of rare diseases. For example, Alpers disease and Barth syndrome are very different and rare forms of mitochondrial Read More >
Health
Leave a comment
Email This Post
Tags: advocacy, ALS, alzheimers, awareness, cancer, diabetes, FDA, FDASIA, genetic, health, Health Care, healthcare, lou gehrig's disease, lupus, mitochondria, mitochondrial disease, mitochondrial dysfunction, MS, Multiple sclerosis, mutation, NORD, ODTC, Orphan Drug Tax Credit, orphan drugs, Parkinson's, patient, patient advocacy, patient advocates, Patient community, patients, rare disease, Rare Disease Drug Development, rare diseases, rheumatoid arthritis
Tags: advocacy, ALS, alzheimers, awareness, cancer, diabetes, FDA, FDASIA, genetic, health, Health Care, healthcare, lou gehrig's disease, lupus, mitochondria, mitochondrial disease, mitochondrial dysfunction, MS, Multiple sclerosis, mutation, NORD, ODTC, Orphan Drug Tax Credit, orphan drugs, Parkinson's, patient, patient advocacy, patient advocates, Patient community, patients, rare disease, Rare Disease Drug Development, rare diseases, rheumatoid arthritis
Rare Disease Day 2014: Joining Together for Better Care
There are more than 6,000 different rare diseases affecting over 60 million people across Europe and North America, alone, and millions more throughout the world. Most of these diseases are genetic, serious, chronic and debilitating. Each disease is different, but they affect people in similar ways. Joining together can help patients and their families find common solutions for care and remind them they are not alone. As the world marks Rare Disease Day on February Read More >
